Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
ON001. Anti-TNF antibodies down-regulate mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease
ON001. Nurse's perception on IBD patients' satisfaction with healthcare services
ON002. Efficacy of nurse-driven outpatient clinic for follow-up of inflammatory bowel disease patients on treatment with thiopurinic immunosuppresants
ON002. Hospital Anxiety and Depression Scale (HADS) and self perception: Preliminary results from a multidisciplinary approach in a small cohort of IBD patients
ON002. Simple question, simple answer, complex implications: What does a distress thermometer tell us about disease activity and quality of life in IBD patients?
Authors:

D. Keegan1, K. Byrne1, E. McDermott1, N. Rafter1, G. Cullen1, G. Doherty1, H. Mulcahy1, 1St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland

ON003. From motivated and compliant to empowered: Do we need an IBD nurse led self management programme?
ON003. Inflammatory Bowel Disease Telephone Helplines – An audit of 9 sites across Yorkshire and Humber region, United Kingdom
Authors:

Y. Houston1, M. Rawle2, D. Patterson2, L. Rook2, 1Yorkshire & Humber IBD Network, Hull Royal Infirmary, Dept of Gastroenterology, Hull, United Kingdom, 2Yorkshire & Humber IBD Network, United Kingdom

ON003. The perception of inflammatory bowel disease nurses on transition of adolescents with colitis & Crohn's disease from paediatric to adult services
OP001.

Innate lymphoid cells accumulate in IBD

Authors:

A. Geremia, C. Arancibia, A. Gwela, R.W. Chapman, S.P.L. Travis, F. Powrie, University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom

OP001

Transmissive Crohn's disease-like ileitis is caused by functional dysbiosis in the intestinal microbiota independent of inflammation-driven Paneth cell failure

Authors:

M. Schaubeck*1, T. Clavel2, I. Lagkouvardos1, J. Calasan1, S.B. Haange3, N. Jehmlich3, M. von Bergen4, M. Basic5, A. Bleich6, D. Haller2

Table 1. 

Proportion of patients with mucosal healing (MH — Mayo 0 or 1) by treatment group, visit, and extent of evaluation. n= No. of patients with mucosal healing; N= total no. of patients with evaluable videos. P values: vs placebo.






1Technische Universität München, Chair of Nutrition and Immunology, Weihenstephan, Germany, 2Technische Universität München, Chair of Nutrition and Immunology, Freising-Weihenstephan, Germany, 3Helmholtz-Centre for Environmental Research, UFZ, Department of Proteomics, Leipzig, Germany, 4University of Aalborg, Department of Biotechnology, Aalborg, Denmark, 5Hannover Medical School, Institute for Laboratory AnimHannover Medical School, Hannover, Germany, 6Hannover Medical School, Institute for Laboratory AnimHannover Medical School, Hannover, Germany

OP002.

The GCN2/eIF2α/ATF4 signaling pathway is necessary for autophagy response to infection with Crohn's disease-associated adherent-invasive Escherichia coli

Authors:

H. Nguyen1, J. Carriere1, G. Dalmasso1, A.-C. Maurin2, A. Bruhat2, A. Darfeuille-Michaud1, 1University of Auvergne, UMR 1071/Inserm, Clermont-Ferrand, France, 2INRA, Human nutrition unit (UNH), Theix, France

OP002

UK IBD twin and multiplex registry: Concordance and environmental risk factors of twins with IBD

Authors:

H. Gordon*1, T. Orchard2, A. Steel1, M. Harbord1

1Chelsea and Westminster Hospital, Gastroenterology, London, United Kingdom, 2St Mary's Hospital, Gastroenterology, London, United Kingdom

OP003.

Circadian clock function maintains mucosal architecture and protects against intestinal inflammation in mice

Authors:

R. Pagel, F. Bär, T. Schröder, J. Büning, K. Fellermann, C. Sina, University Hospital Schleswig-Holstein, Campus Lübeck, Medical Department I, Gastroenterology, Lübeck, Germany

OP003

Faecal microbiota transplantation in Ulcerative Colitis: A randomised controlled trial

Authors:

N. Rossen*1, S. Fuentes2, M. van der Spek1, J. Tijssen3, J. Hartman2, A. Duflou1, L. Mathus-Vliegen1, W. de Vos2, E. Zoetendal2, G. D'haens1, C. Ponsioen1

1Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands, 2Wageningen University, Laboratory of Microbiology, Wageningen, Netherlands, 3academic medical center, cardiology, Amsterdam, Netherlands

OP004.

Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial

Authors:

R. Khanna1, B.G. Levesque1,2, B. Bressler3, G. Zou1,4, L. Stitt1, G.R. Greenberg5, R. Panaccione6, A. Bitton7, P. Pare8, S. Vermeire9, G. D'Haens1,10, D. MacIntosh11, W.J. Sandborn1,2, M.K. Vandervoort1, J.C. Morris1, B.G. Feagan1,12, 1Robarts Clinical Trials Inc., Robarts Research Institute, Western University, London, Ontario, Canada, 2University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 3St. Paul's Hospital, Department of Gastroenterology, Vancouver, British Columbia, Canada, 4Western University, Department of Epidemiology and Biostatistics, London Ontario, Canada, 5Mount Sinai Hospital, Division of Gastroenterology, Toronto Ontario, Canada, 6University of Calgary, Division of Gastroenterology & Hepatology, Calgary Alberta, Canada, 7McGill University, Division of Gastroenterology, Montreal Quebec, Canada, 8Laval University, Hopital du St-Sacrement, Quebec City, Quebec, Canada, 9Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 10University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 11Dalhousie University, Division of Gastroenterology, Halifax, Canada, 12Western University, Department of Epidemiology and Biostatistics, Department of Medicine, London Ontario, Canada

OP004

Adalimumab and infliximab levels in neonates (ERA study)

Authors:

M. Julsgaard*1, 2, L.A. Christensen1, P.R. Gibson3, R. Gearry4, J. Fallingborg5, J. Kjeldsen6, S. Wildt7, L. Svenningsen8, W. Connell2, C.L. Hvas1, M.P. Sparrow3, A. Walsh9, S.J. Connor10, G. Radford-Smith11, I. Lawrence12, J.M. Andrews13, K. Ellard14, O. Rosella3, A. Grosen1, J. Santamaria15, S.J. Bell2

1Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, 2St Vincent's Hospital & University of Melbourne, Department of Gastroenterology, Melbourne, Australia, 3Alfred Hospital and Monash University, Department of Gastroenterology, Melbourne, Australia, 4University of Otago, Christchurch Hospital, Department of Medicine and Gastroenterology, Christchurch, New Zealand, 5Aalborg Hospital, Department of Gastroenterology, Aalborg, Denmark, 6Odense University Hospital, Department of Gastroenterology and Hepatology, Odense, Denmark, 7Koege Hospital, Department of Gastroenterology, Koege, Denmark, 8Herning Hospital, Department of Medicine and Gastroenterology, Herning, Denmark, 9St. Vincent's hospital , Department of Gastroenterology, Sydney, Australia, 10Liverpool Hospital & University of NSW, Dept. of Gastroenterology, Sydney, Australia, 11Royal Brisbane & Women's Hospital, Department of Gastroenterology, Brisbane, Australia, 12Fremantle Hospital, Centre for Inflammatory Bowel Disease, Fremantle, Australia, 13Royal Adelaide Hospital, University of Adelaide , IBD Service, Dept of Gastroenterology & Hepatology & School of Medicine, Adelaide, Australia, 14Royal North Shore Hospital, Department of Gastroenterology, Sydney, Australia, 15St Vincent's Hospital & University of Melbourne, Department of Intensive Care, Melbourne, Australia

OP005.

Is elderly-onset ulcerative colitis a different entity? – Natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort

Authors:

S. Jeuring1,2, T. Van den Heuvel1,2, M. Zeegers3,4, W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1,2, D. Jonkers1,2, M. Pierik1,2, 1Maastricht University Medical Center+, Internal Medicine – Division Gastroenterology-Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Center+, NUTRIM, School for Nutrition, Toxicology and Metabolism, Maastricht, Netherlands, 3University of Birmingham, Epidemiology and Public Health, Birmingham, United Kingdom, 4Maastricht University Medical Center+, Complex Genetics, Cluster of Genetics and Cell Biology, Maastricht, Netherlands, 5ORBIS Medical Centre, Gastroenterology and Hepatology, Sittard, Netherlands, 6Atrium Medical Center, Internal Medicine and Gastroenterology, Heerlen, Netherlands

OP005

Infliximab trough level thresholds vary depending on the efficacy criterion chosen in IBD patients

Authors:

X. Roblin*1, M. Rinaudo2, C. Jarlot1, E. Del Tedesco1, J.M. Phelip1, L. Clavel1, L. Peyrin Biroulet3, S. Paul2

1University Hospital, Gastroenterology, Saint Etienne, France, 2University of Saint Etienne, Immunology, Saint Etienne, France, 3CHU de Nancy, Department of Gastroenterology, Vandoeuvre-les-Nancy, France

OP006.

Personalized thiopurine dosing based on TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients. Results from a randomized trial in the Netherlands

Authors:

M. Coenen1, C. van Marrewijk1, L. Derijks2, S. Vermeulen1,3, D. Wong4, O. Klungel5, A. Verbeek3, P. Hooymans4, H. Scheffer1, H.-J. Guchelaar6, B. Franke1,7, D. de Jong8, 1Radboud university medical center, Human Genetics, Nijmegen, Netherlands, 2Máxima Medical Centre, Clinical Pharmacy, Veldhoven, Netherlands, 3Radboud university medical center, Health Evidence, Nijmegen, Netherlands, 4Orbis Medical Centre, Clinical Pharmacy and Toxicology, Nijmegen, Netherlands, 5Utrecht Institute of Pharmaceutical Sciences, Pharmacoepidemiology and Pharmacotherapy, Utrecht, Netherlands, 6University Medical Center, Clinical Pharmacy and Toxicology, Leiden, Netherlands, 7Radboud university medical center, Psychiatry, Nijmegen, Netherlands, 8Radboud university medical center, Gastroenterology, Nijmegen, Netherlands

OP006

Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary non-response to infliximab in Crohn's disease patients

Authors:

T. Billiet*1, I. Cleynen1, V. Ballet2, K. Claes1, F. Princen3, S. Singh3, M. Ferrante2, G. Van Assche2, S. Vermeire2

1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 2University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3Prometheus Laboratories, Department of Research and Development, San Diego, United States